[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"extrapulmonary-neuroendocrine-carcinoma-ep-nec\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:extrapulmonary-neuroendocrine-carcinoma-ep-nec":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,47,90,119],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100630534","phase-1-a-first-in-human-fih-phase-1-study-of-ml261-an-autologous-potency-enhanced-anti-dll3-car-t-cell-therapy-in-participants-with-rr-sclc-or-select-necs-spectral-1-100630534",false,"NCT07488923","A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R\u002FR SCLC or Select NECs (SPECTRAL-1)","A Phase 1 First-In-Human Study to Investigate the Safety, Pharmacokinetics and Preliminary Efficacy of ML261, an Autologous Anti-DLL3 CAR + CARD11-PIK3R3 Fusion T Cell Therapy, in Participants With Relapsed\u002FRefractory Small Cell Lung Cancer or Select Neuroendocrine Carcinomas","Inclusion Criteria\n\n* ≥18 years of age at the time of signing the ICF\n* Have been previously treated with at least one line of systemic standard of care (SOC) anti-cancer therapy for their respective cancer indication. Participants with locally advanced disease who are eligible for curative resection will be excluded.\n* Have documented radiological disease progression\u002Frelapse during or after their most recent line of anti-cancer therapy with measurable disease on imaging, as assessed by RECIST v1.1\n* Have histologically and\u002For cytologically confirmed diagnosis of select advanced or metastatic R\u002FR solid tumor malignancy in one of the following: R\u002FR SCLC, R\u002FR GEP-NEC, R\u002FR high-grade NEPC, R\u002FR epNEC with biopsy-documented DLL3 expression on archival tissue or fresh biopsy by local or central assessment. CNS NEC is excluded. Participants with mixed histologies for any of these indications qualify if the small cell\u002Fneuroendocrine tumor cell percentage is \\> 50%, except for high-grade NEPC where neuroendocrine component must be \\> 20%.\n* Eastern Cooperative Oncology Group (ECOG) Performance Score (PS) 0 or 1\n* Life expectancy ≥12 weeks\n* Have adequate hematologic and end-organ function\n\nExclusion Criteria:\n\n* Previous systemic anti-cancer therapies within the timeframes, as specified in the protocol.\n* Prior exposure\u002Ftreatment with DLL3-targeted CAR T therapy or any other genetically engineered adoptive T cell therapy.\n* Prior allogeneic organ transplant (including allogeneic bone marrow transplant).\n* Major surgical procedure within 4 weeks of the first dose of any study drug administration or anticipated to be in need of a major surgical procedure during the course of study.\n* Participants with toxicities (as a result of prior anti-cancer therapy) which have not recovered to baseline or CTCAE v5.0 \\\u003CGrade 2, except for adverse events (AEs) not considered a likely safety risk: (e.g., alopecia, neuropathy, non-clinically relevant laboratory abnormalities).\n* Symptomatic ascites or effusions (pleural or pericardial) requiring intermittent drainage.\n* History of any other malignancy known to be active, with the exception of completely removed in situ cervical intra-epithelial neoplasia, non-melanoma skin cancer, ductal carcinoma in situ, early-stage prostate cancer that has been adequately treated, and other cancers from which the participant has been disease free for 3 years or longer or does not require treatment and in the opinion of investigator after discussion with the medical monitor are not likely to impact the patient's life expectancy.\n* One or more of the following cardiac criteria: Unstable angina, Myocardial infarction within 6 months prior to Screening, New York Heart Association Class III to IV heart failure, clinically important abnormalities in rhythm, conduction, or morphology of resting ECG (e.g., complete left bundle branch block or third-degree heart block)\n* Acute venous thromboembolism (VTE). VTEs without hemodynamic compromise, treated with stable doses of anticoagulants are allowed.\n* Presence of clinically significant CNS pathology:\n\n  * seizure disorder, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, or cerebellar disease. History of these disorders requires discussion with the medical monitor.\n  * Presence of clinically active psychosis.\n  * Known brain metastases unless asymptomatic and not requiring steroids for at least 2 weeks prior to the first dose of any study drug administration.\n* Active systemic autoimmune disease or any other condition that requires, or is anticipated to require, systemic treatment with steroids or other systemic immunosuppressive agents, or participants who have received such agents within 4 weeks of leukapheresis and ML261 administration (further details provided in protocol body).\n* Evidence of interstitial lung disease (such as idiopathic pulmonary fibrosis) or active pneumonitis of any etiology requiring treatment.\n* Any active infection (defined as symptoms, signs, or radiographic) of bacterial, viral, or fungal or unknown etiology requiring systemic therapy within 14 days of leukapheresis. Participants with clinical and\u002For laboratory evidence of persistent infection will be excluded.\n* Uncontrolled medical, psychological\u002Fpsychiatric, or social condition that would interfere with the participant's participation or compromise the objectives of the study in the opinion of the Investigator and\u002For the Sponsor.","ALL","18 Years",{"count":19,"type":20},110,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","This is a first-in-human (FIH), open-label, Phase 1 study designed to evaluate the safety, pharmacokinetics (PK), and preliminary efficacy of ML261, an autologous potency enhanced anti-DLL3 CAR T cell therapy, in participants with R\u002FR SCLC or select NECs",[26,27,28,29],"Small Cell Lung Cancer (SCLC )","Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)","Gastroenteropancreatic NEC (GEP NEC)","Neuroendocrine Prostate Cancer (NEPC)",[31,32,33],"Neuroendocrine carcinoma","DLL3","CAR T","NOT_YET_RECRUITING","2026-06-22",{"date":37,"type":38},"2026-06-25","ACTUAL",{"date":40,"type":20},"2026-06",{"date":42,"type":20},"2030-08",{"name":44,"class":45},"Moonlight Bio, Inc","INDUSTRY",5,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":58,"conditions":59,"keywords":65,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":46},"100614352","phase-1-study-of-212pbpb-dotam-mam279-212pbpb-mp0712-in-patients-with-small-cell-lung-cancer-and-other-dll3-expressing-solid-tumors-100614352","NCT07278479","Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors","A Phase 1\u002F2a Study to Assess Safety, Tolerability, and Efficacy of [212Pb]Pb-DOTAM-MAM279 in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors","Key Inclusion Criteria:\n\n* Age ≥ 18 years old\n* Histologically or cytologically confirmed: I. advanced extensive or limited SCLC or LC NECs of the lung\n\n  * SCLC (extensive stage, or limited stage) patients with progression or recurrence following at least two prior line of systemic platinum based therapy and immunotherapy or are not suitable or tolerating the standard of care treatment as second line of systemic therapy, or\n  * LC NEC of the lung patients with progression or recurrence following at least one prior line of systemic therapy, or II. epNECs with progression or recurrence following at least one prior line of systemic therapy:\n  * Gastroenteropancreatic NECs (GEPNEC), or\n  * Cervical NECs, or\n  * Bladder NECs, or\n  * other epNECs with previously confirmed DLL3 expression by IHC.\n  * Patients with prior DLL3-targeted therapy are allowed.\n* For epNECs in Part 1 and Part 2 and SCLC or LC NECs of the lung in Part 2: DLL3-positivity by \\[203Pb\\]Pb-DOTAM-MAM279 SPECT\u002FCT\n* Radiographically documented disease progression or recurrence during or after the last line of systemic treatment therapy\n* At least one measurable disease per RECIST v1.1.\n* Adequate bone marrow reserve and organ function as demonstrated by complete blood count, and biochemistry in blood and urine at Screening\n* Adequate blood counts: Hemoglobin ≥9 g\u002FdL; Absolute neutrophil count (ANC) ≥1.5 × 10\\^9\u002FL; Platelets ≥100 × 10\\^9\u002FL; White blood cells (WBC) ≥2.5 x 10\\^9\u002FL;\n* Adequate hepatic function\n* Adequate renal function: Calculated glomerular filtration rate (GFR) \\>60mL\u002Fmin (using Cockroft-Gault formula).\n* Patients with known central nervous system (CNS) metastasis will be eligible if they are clinically stable.\n\nKey Exclusion Criteria:\n\n* Uncontrolled intercurrent illness\n* Patients who have not had resolution of all clinically significant toxic effects of prior systemic cancer therapy, surgery, or radiotherapy to Grade ≤1 (except for grade ≤2 alopecia, or stable grade 2 sensory neuropathy, according to the last CTCAE version).\n* Active clinically significant cardiac disease\n* Evidence of interstitial lung disease or active, non-infectious pneumonitis.\n* History of other malignancy within the past 2 years with exceptions.\n\nOther protocol-defined inclusion\u002Fexclusion criteria may apply.",{"count":55,"type":20},138,[23,57],"PHASE2","The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \\[212Pb\\]Pb-MP0712, in patients aged ≥18 years with Small Cell Lung Cancer and other locally advanced or metastatic DLL3 positive tumors.",[60,61,27,62,28,63,64],"Large Cell Neuroendocrine Carcinoma","Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC)","Small Cell Lung Cancer (SCLC)","NEC of the Bladder","Other DLL3 Expressing epNEC",[66,67,68,69,32,70,71,72,73,74,75,76,77,78,79],"DARPin","Alpha Emitter","Pb203","Pb212","Radioligand therapy (RLT)","SCLC","Neuroendocrine cancer","[203Pb]Pb-DOTAM-MAM279","[212Pb]Pb-DOTAM-MAM279","EP-NEC","Lead 212","Lead 203","203Pb","212Pb","RECRUITING","2026-05-21",{"date":83,"type":38},"2026-05-22",{"date":85,"type":38},"2026-05-18",{"date":87,"type":20},"2032-09",{"name":89,"class":45},"Molecular Partners AG",{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":97,"enrollmentInfo":98,"targetDuration":4,"studyType":21,"phases":100,"briefSummary":101,"conditions":102,"keywords":103,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":118},"100632816","phase-2-efficacy-and-safety-of-chidamidesintilimabbev-as-second-line-therapy-in-advanced-extrapulmonary-neuroendocrine-carcinoma-100632816","NCT07518602","Efficacy and Safety of Chidamide+Sintilimab+Bev as Second-Line Therapy in Advanced Extrapulmonary Neuroendocrine Carcinoma","Evaluation of Efficacy and Safety of Chidamide+Sintilimab+Bevacizumab in Subjects With Advanced Extrapulmonary Neuroendocrine Carcinoma Who Have Failed First-Line Standard Therapy: A Single-Arm, Phase II, Multicenter Study","Inclusion Criteria:\n\n1. Histologically or cytologically confirmed locally advanced, unresectable, or metastatic extrapulmonary neuroendocrine carcinoma (NEC).\n2. Failure of first-line standard systemic therapy, with documented disease progression during or after treatment by imaging or clinical evidence (e.g., cytology of new ascites or pleural effusion). Patients who discontinued first-line therapy due to intolerable toxicity are eligible.\n3. At least one measurable lesion per RECIST version 1.1.\n4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n5. Able to provide written informed consent and comply with study visits and procedures.\n6. Age ≥ 18 years and ≤ 75 years.\n7. Life expectancy ≥ 12 weeks.\n8. Women of childbearing potential and men with female partners of childbearing potential must use effective contraception throughout the treatment period and for 6 months after the last dose of study treatment.\n9. Adequate organ and bone marrow function within 7 days before enrollment, without support treatments (blood products, growth factors, albumin) within 14 days before testing: absolute neutrophil count (ANC) ≥ 1.5 × 10⁹\u002FL; platelet count (PLT) ≥ 100 × 10⁹\u002FL; hemoglobin (HGB) ≥ 9.0 g\u002FdL; serum total bilirubin (TBIL) ≤ 1.5 × upper limit of normal (ULN); ALT\u002FAST ≤ 3.0 × ULN (no liver metastasis) or ≤ 5.0 × ULN (with liver metastasis); serum albumin ≥ 25 g\u002FL; serum creatinine (Cr) ≤ 1.5 × ULN; urine protein \\\u003C 2+ or 24-hour urine protein \\\u003C 1 g if urine protein ≥ 2+; INR ≤ 1.5 × ULN and APTT ≤ 1.5 × ULN.\n\nExclusion Criteria:\n\n1. Prior exposure to any anti-angiogenic therapy or histone deacetylase (HDAC) inhibitor.\n2. Received any investigational drug within 4 weeks before the first dose of study treatment.\n3. Simultaneously participating in another interventional clinical study (observational or follow-up studies are allowed).\n4. Received last dose of anti-tumor therapy (chemotherapy, targeted therapy, immunotherapy, embolization, etc.) within 3 weeks before first dose.\n5. Received radiotherapy within 4 weeks before first dose.\n6. Residual radiation-related toxicity (e.g., pneumonitis, hepatitis, enteritis) from prior radiotherapy \\> 4 weeks before first dose, including symptomatic cases or those requiring corticosteroids.\n7. Received systemic immunosuppressive drugs within 4 weeks before first dose, except topical\u002Finhaled corticosteroids or physiological systemic corticosteroids (≤ 10 mg\u002Fday prednisone equivalent).\n8. Received or plans to receive live attenuated vaccines within 4 weeks before first dose or during the study.\n9. Underwent major surgery within 4 weeks before first dose, or has unhealed wounds, ulcers, or fractures.\n10. Resolved toxicity from prior anti-tumor therapy not recovered to NCI CTCAE version 5.0 grade ≤ 1 (except alopecia or non-clinically significant laboratory abnormalities).\n11. Known symptomatic central nervous system (CNS) metastases or carcinomatous meningitis. Patients with treated and stable CNS metastases for ≥ 4 weeks and neurological symptoms recovered to grade ≤ 1 are allowed.\n12. Active autoimmune disease requiring systemic therapy within 2 years before first dose; or primary immunodeficiency. Replacement therapy (e.g., thyroid hormone, insulin) is permitted.\n13. Active tuberculosis, or anti-tuberculosis treatment within 1 year before first dose.\n14. Interstitial lung disease requiring corticosteroid treatment.\n15. Active hepatitis B (HBsAg positive and HBV DNA ≥ 200 IU\u002FmL) or active hepatitis C (HCV antibody positive and HCV RNA positive).\n16. Known HIV infection or syphilis.\n17. Severe uncontrolled active infection, including hospitalization for infection within 4 weeks before first dose.\n18. Significant malnutrition requiring intravenous nutrition, unless corrected for \\> 4 weeks before first dose.\n19. Symptomatic congestive heart failure (NYHA class II-IV), or symptomatic\u002Funcontrolled arrhythmia.\n20. Uncontrolled arterial hypertension despite optimal treatment (systolic BP ≥ 150 mmHg or diastolic BP ≥ 100 mmHg).\n21. Any arterial thromboembolic event (myocardial infarction, pulmonary embolism, unstable angina) within 6 months before enrollment.\n22. History of deep vein thrombosis or other severe thromboembolism within 3 months before enrollment (catheter-related or superficial vein thrombosis excluded).\n23. Hepatic encephalopathy, hepatorenal syndrome, or Child-Pugh B or C cirrhosis.\n24. History of gastrointestinal perforation\u002Ffistula, peptic ulcer, bowel obstruction, extensive bowel resection, Crohn's disease, ulcerative colitis, intra-abdominal abscess, or chronic diarrhea within 6 months before enrollment; or intestinal stent placement.\n25. Uncontrolled metabolic disorders or other severe medical conditions that may increase study risk or confound result interpretation.\n26. Hereditary bleeding tendency or coagulation disorder.\n27. Any life-threatening bleeding event within 3 months before enrollment (requiring transfusion, surgery, or continuous treatment).\n28. High bleeding risk per investigator assessment: severe esophageal\u002Fgastric varices, intermittent bleeding (e.g., hematochezia, hemoptysis).\n29. Cerebrovascular accident (including transient ischemic attack) within 6 months before enrollment.\n30. Use of aspirin (\\> 325 mg\u002Fday) or other platelet inhibitors for 10 consecutive days within 10 days before first dose.\n31. Use of oral or parenteral anticoagulants or thrombolytics for 10 consecutive days within 10 days before first dose (prophylactic anticoagulation allowed).\n32. Symptomatic or drainable pleural effusion, ascites, or pericardial effusion (only small asymptomatic effusions by imaging are allowed).\n33. History of other primary malignancy, except: Malignancy in complete remission for ≥ 2 years without treatment during study；adequately treated non-melanoma skin cancer or carcinoma in situ with no evidence of recurrence.\n34. History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.\n35. Known hypersensitivity to any monoclonal antibody component or study drug excipients.\n36. Pregnant or breastfeeding female patients.\n37. History of alcoholism or drug abuse.\n38. Any other acute or chronic disease, psychiatric disorder, or laboratory abnormality that, in the investigator's opinion, increases study risk or interferes with result interpretation.","75 Years",{"count":99,"type":20},34,[57],"This is a single-arm, multicenter phase Ⅱ study to evaluate the therapeutic efficacy and safety of chidamide + sintilimab + bevacizumab in subjects with advanced extrapulmonary neuroendocrine carcinoma who have failed first-line standard therapy. The primary purpose is to assess the objective response rate (ORR) of chidamide + sintilimab + bevacizumab in the above-mentioned subjects, with a planned enrollment of 34 subjects with advanced extrapulmonary neuroendocrine carcinoma who have failed first-line standard therapy.",[27],[104,105,106,107],"extrapulmonary neuroendocrine carcinoma","chidamide","sintilimab","bevacizumab","2026-04-02",{"date":110,"type":38},"2026-04-08",{"date":112,"type":20},"2026-03-27",{"date":114,"type":20},"2028-09-27",{"name":116,"class":117},"Sun Yat-sen University","OTHER",1,{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":126,"targetDuration":4,"studyType":21,"phases":128,"briefSummary":129,"conditions":130,"keywords":134,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":155},"100489405","phase-1-a-study-of-peluntamig-pt217-in-patients-with-neuroendocrine-carcinomas-expressing-dll3-the-skybridge-study-100489405","NCT05652686","A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)","An Open-label, Multicenter, Dose Escalation, and Dose Expansion Phase 1\u002F2 Study With Peluntamig (PT217) Followed by a Key ChemotherapY and\u002For Checkpoint Inhibitor ComBination in Patients With NeuRoendocrIne Carcinomas That Are Known to be DLL3 expressinG CancErs (SKYBRIDGE)","Key Inclusion Criteria\n\n1. NECs that have transformed from NSCLC are not eligible. Part A: Patients with histologically or cytologically confirmed unresectable advanced or metastatic small cell lung cancer (SCLC), large cell neuroendocrine carcinoma of the lung (LCNEC), or extrapulmonary neuroendocrine carcinoma (EP-NEC). Patients with tumors that are of mixed histology are eligible only if neuroendocrine carcinoma\u002Fsmall cell cancer component is predominant and represents at least 50% of the overall tumor tissue. Patients with well differentiated grade 3 neuroendocrine tumors (Ki-67 ≥ 55%) may be considered if their tumors are DLL3 positive.\n\n   Patients may have progressed after standard of care treatments (at least one line of platinum-based chemotherapy with or without immune checkpoint inhibitor for SCLC patients) or other treatment options, or for whom treatment is not available or not tolerated.\n\n   Part B: Patients must meet the same criteria in Part A, C or D.\n\n   Part C:\n\n   • Cohort C1: patients with LCNEC or EP-NEC eligible for first-line (1L) CE treatment. SCLC patients who have relapsed on a 1L treatment (including platinum-based therapy with or without ICI) but remain platinum sensitive (defined as patients who experienced disease progression at least 90 days after their last platinum based chemotherapy) and are eligible for CE treatment rechallenge.\n\n   Cohort C2: patients with SCLC, LCNEC and EP-NEC eligible for second line (2L) paclitaxel treatment.\n\n   Part D:\n   * Cohort D1: will include 2L patients with SCLC, LCNEC, pr EP-NEC that have progressed\u002Frelapsed from their first-line treatment that may have included an ICI.\n   * Cohort D2: will include 1L ES-SCLC patients that have completed their induction therapy with carboplatin and etoposide plus atezolizumab and are eligible to continue with atezolizumab. These patients must have either stable disease or partial response prior to enrollment.\n   * Cohort D3: will include 1L ES-SCLC patients that are treatment naïve or have received C1D1\u002F2\u002F3 and are eligible for treatment with CE plus atezolizumab.\n2. Able to provide a formalin fixed, paraffin embedded (FFPE) tumor tissue sample (preferably a newly acquired biopsy, or if not possible, archival tissue) to be assessed for DLL3 expression and other biomarkers.\n3. ECOG performance status of 0 or 1.\n4. Adequate organ function confirmed at screening and within 72 hours of initiating C1D1 of Peluntamig (PT217) treatment.\n\nKey Exclusion Criteria\n\n1. Women who are pregnant or lactating.\n2. Women of child-bearing potential (WOCBP) who do not use adequate birth control.\n3. Autoimmune disease requiring systemic treatment within the past twelve months.\n4. Treatment with systemic immunostimulatory agents (including, but not limited to, interferon and IL-2, and excluding ICIs) within 4 weeks or 5 drug-elimination half-lives (whichever is longer) prior to initiation of study treatment with Peluntamig (PT217).\n5. Condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications (≥ 10 mg prednisone, or equivalent) within 14 days prior to study drug Peluntamig (PT217), or anticipation of need for systemic immunosuppressive medication during study drug Peluntamig (PT217).\n6. Patients who have experienced Grade ≥ 3 immune-related events, such as (non-infectious) pneumonitis, interstitial lung disease, myocarditis.\n7. Treatment with therapeutic oral or i.v. antibiotics within 2 weeks prior to initiation of study treatment with Peluntamig (PT217).\n8. Patients with untreated brain or central nervous system (CNS) metastases or brain\u002FCNS metastases that have progressed.\n\n   Note: Patients with treated brain metastases that are off corticosteroids and have been clinically stable for 14 days are eligible for treatment.\n9. Impaired cardiac function or significant diseases.\n10. For Part D only, uncontrolled hypercalcemia.\n11. For Part D only, significant cardiovascular disease (such as New York Heart Association Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina.\n12. Prior hemolytic anemia or Evans Syndrome in the last 3 months.\n13. Patients who have Grade ≥ 3 neuropathy.\n14. Patients who are currently receiving treatment with therapeutic doses of warfarin sodium (Coumadin®) or any other coumarin-derivative anticoagulants .\n\nAdditional criteria may apply.",{"count":127,"type":20},203,[23,57],"This is a first-in-human, Phase 1\u002F2, open-label, dose escalation, dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Peluntamig (PT217) as a monotherapy and in combination with chemotherapy.",[62,131,29,132,133,27],"Large Cell Neuroendocrine Cancer (LCNEC)","Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)","Neuroendocrine Carcinomas (NEC)",[32,135,136,71,137,138,139,140,141,142,143,31,144,75,145],"DLL3 expressing tumors","Lung cancer","LCNEC","NEPC","GEP-NEC","Small Cell Lung Cancer","Large cell neuroendocrine cancer","Neuroendocrine prostate cancer","Gastroenteropancreatic neuroendocrine carcinoma","Extrapulmonary neuroendocrine carcinoma","CD47","2025-09-18",{"date":148,"type":38},"2025-09-23",{"date":150,"type":38},"2023-09-05",{"date":152,"type":20},"2028-08",{"name":154,"class":45},"Phanes Therapeutics",12]